ANIX Valuation

Anixa Biosciences Inc

Add to Watchlist

Advanced Chart

3.370

0(0.000%)1D

Overview
Forecast
Valuation
Earnings

ANIX Relative Valuation

ANIX's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, ANIX is overvalued; if below, it's undervalued.

Historical Valuation

Anixa Biosciences Inc (ANIX) is now in the Fair zone, suggesting that its current forward PS ratio of 0.00 is considered Fairly compared with the five-year average of -8.66. The fair price of Anixa Biosciences Inc (ANIX) is between NaN to NaN according to relative valuation methord.

Relative Value

Fair Zone

NaN-NaN

Current Price：3.37

Fair

Trailing

Forward

P/E

EV/EBITDA

EV/EBIT

P/S

P/OCF

P/FCF

Trailing

Forward

6.78

P/B

Median3y

4.63

Median5y

4.82

-7.43

FCF Yield

Median3y

-6.51

Median5y

-6.35

Competitors Valuation Multiple

The average P/S ratio for ANIX's competitors is 5.26, providing a benchmark for relative valuation. Anixa Biosciences Inc Corp (ANIX) exhibits a P/S ratio of 0.00, which is -100.00% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.

P/S

P/E

EV/EBITDA

EV/EBIT

P/S

Revenue Growth

Market Cap

ANIX.O

Anixa Biosciences Inc

Loss

Average P/S: 5.26

108.55M